TrialThe Lancet. Infectious diseases2021

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.

Shipo Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.